Biomarkers come of age: PD1 in the frontline and cell cycle therapy swells the ranks of personalised therapy in the European Society of Medical Oncology (ESMO) congress, Copenhagen, 7–10 October 2016

After years of trials, Programmed Death Ligand and Receptor targeting finally debuts as a firstline therapy in combination and as a single agent regimen at the 2016 European Society of Medical Oncology (ESMO) Congress. The meeting brought together 20,522 attendees, from over 120 countries, to share...

Descripción completa

Detalles Bibliográficos
Autor principal: Davies, Will
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cancer Intelligence 2016
Materias:
Conference Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5221637/
https://www.ncbi.nlm.nih.gov/pubmed/28105074
http://dx.doi.org/10.3332/ecancer.2016.703

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5221637/
https://www.ncbi.nlm.nih.gov/pubmed/28105074
http://dx.doi.org/10.3332/ecancer.2016.703

Ejemplares similares